FVIII MUTEINS FOR TREATMENT OF VON WILLEBRAND DISEASE

This invention relates to treatment of von Willebrand Disease by administration of Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant a...

Full description

Saved in:
Bibliographic Details
Main Authors LIU TONGYAO, JIANG HAIYAN, PAN JUNLIANG, PIERCE GLENN, ZHANG XIN, MURPHY JOHN E
Format Patent
LanguageEnglish
Korean
Published 21.02.2011
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention relates to treatment of von Willebrand Disease by administration of Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties in subjects lacking von Willebrand Factor.
Bibliography:Application Number: KR20117000028